Culmination Bio News Today

Culmination Bio, a data and technology company combining clinical and biospecimen data, announced a partnership with BillionToOne, Inc., a next-generation molecular diagnostics company

BioPharma

Merck has signed a R&D collaboration deal with data and technology company Culmination Bio, a spinoff from Intermountain Health.

Culmination Bio, a data and technology company combining clinical and biospecimen data, announced an R&D collaboration with Merck, known as MSD, outside the United States and Canada, initially in the area of autoimmune disease.

BioPharma

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Culmination Bio, a patient data intelligence platform spun off from Intermountain Health, has received a $10 million investment. The platform has a library of 5

Culmination Bio, a company building the largest disease-agnostic patient data intelligence platform, today announced a $10 million…

Culmination Bio, a company building the largest disease-agnostic patient data intelligence platform, today announced a $10 million investment from Merck Global Health Innovation Fund (Merck GHI) and Amgen Ventures. As a spinoff from Intermountain Health, Culmination Bio maintains exclusive rights to a physical library and cloud-based data lake covering over 40 years of de-identified patient electronic health records and biospecimen data. As the most extensive data lake of its kind, it...

New biotech company will improve precision medicine and drive clinical discovery to benefit patients